BEHANDLUNG DES HYPERINFLAMMATORISCHEN SYNDROMS

European patent · EP4125843 · In force

Register entry

Publication number
EP4125843
Application number
EP21717576
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 31, 2021
Published
Feb 8, 2023
Granted
May 21, 2025
Protection ends at the latest
Mar 30, 2041
Next annual fee due
Mar 31, 2027
IPC classes
A61K 31/167 (2006.01)
A61P 11/00 (2006.01)
A61P 11/16 (2006.01)
A61K 31/00 (2006.01)
A61K 9/00 (2006.01)
A61K 9/70 (2006.01)
A61K 47/44 (2017.01)
A61P 1/06 (2006.01)
A61P 9/10 (2006.01)
A61P 13/02 (2006.01)
A61P 13/10 (2006.01)
A61P 13/12 (2006.01)
A61P 19/02 (2006.01)
A61P 25/02 (2006.01)
A61P 25/08 (2006.01)
A61P 25/28 (2006.01)
A61P 35/00 (2006.01)
A61P 37/00 (2006.01)
A61P 37/08 (2006.01)
Priority
NL 2025253 31.03.2020
NL 2025541 08.05.2020
NL 2027321 14.01.2021
PCT application
PCT/NL2021/050208 31.03.2021
PCT publication
WO2021/201680 07.10.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 2, 2026

    Change

    Published in Swissreg on 02.04.2026

  2. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  3. Jul 8, 2025

    Agent entered

    Representative
    BOVARD AG, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 08.07.2025

  4. May 21, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 21.05.2025

Parties

Holder

Remicine IP B.V.

Leeghwaterweg 1B, 1951 NA Velsen-Noord, NL

Agent

Bovard AG

BOVARD AG

Optingenstrasse 16, 3013 Bern

Inventor

HASAN, Djohan

2460 Kasterlee, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.